ProShares UltraShort NASDAQ Biotechnology
6 hedge funds and large institutions have $859K invested in ProShares UltraShort NASDAQ Biotechnology in 2024 Q1 according to their latest regulatory filings, with 0 funds opening new positions, 3 increasing their positions, 2 reducing their positions, and 0 closing their positions.
56% more capital invested
Capital invested by funds: $550K → $859K (+$309K)
50% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 2
4.6% more ownership
Funds ownership: 7.61% → 12.21% (+4.6%)
0% more funds holding
Funds holding: 6 → 6 (0)
90% less call options, than puts
Call options by funds: $2K | Put options by funds: $21K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
IMC Chicago
Chicago,
Illinois
|
+$180K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$141K |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$11K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
UBS Group
Zurich,
Switzerland
|
-$4.59K |
| 2 |
Morgan Stanley
New York
|
-$2.83K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
IMC Chicago
Chicago,
Illinois
| $443K | +$180K | +5,104 | +68% |
|
|
TRCT
2
Tower Research Capital (TRC)
New York
| $224K | +$141K | +4,003 | +170% |
|
|
3
Citadel Advisors
Miami,
Florida
| $187K | +$11K | +312 | +6% |
|
|
4
Morgan Stanley
New York
| $2.87K | -$2.83K | -80 | -49% |
|
5
Citigroup
New York
| $1.49K | – | – | – |
|
|
6
UBS Group
Zurich,
Switzerland
| $247 | -$4.59K | -130 | -95% |
|
BIS Hedge Fund Activity: Q1 2024 in Review
6 of the 6,943 institutional investors tracked by Wall St. Rank reported a position in ProShares UltraShort NASDAQ Biotechnology (BIS) for Q1 2024, worth a combined $859K — up 56% from $550K a quarter earlier.
Fund positioning in BIS was balanced in Q1 2024: 0 funds opened new positions, 0 closed out, 3 added to existing stakes and 2 trimmed.
The largest buyer was IMC Chicago, adding an estimated $180K. The largest seller was UBS Group, cutting an estimated $4.59K.
- 6 institutional investors held ProShares UltraShort NASDAQ Biotechnology (BIS) as of Q1 2024, unchanged from Q4 2023.
- Funds reported $859K of ProShares UltraShort NASDAQ Biotechnology stock for Q1 2024, up 56% quarter-over-quarter.
- 0 funds opened new ProShares UltraShort NASDAQ Biotechnology positions in Q1 2024 and 0 closed out.
- The largest ProShares UltraShort NASDAQ Biotechnology buyer in Q1 2024 was IMC Chicago, an estimated $180K added.
- The largest ProShares UltraShort NASDAQ Biotechnology seller in Q1 2024 was UBS Group, an estimated $4.59K sold.
Based on aggregated 13F filings for Q1 2024.